Nanomolar CFTR Inhibition by Pore-Occluding Divalent Polyethylene Glycol-Malonic Acid Hydrazides

Chemistry and Biology

Volumn 15, Issue 7, 2008, Pages 718-728

  Sonawane, N D ^a   Zhao, Dan ^a   Zegarra Moran, Olga ^b   Galietta, Luis J V ^b   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

CELLBIO; CHEMBIO; SIGNALING

Indexed keywords

CHOLERA TOXIN; HYDRAZINE DERIVATIVE; MACROGOL DERIVATIVE; MALONIC ACID; MALONIC ACID DERIVATIVE; STILBENE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATCH CLAMP; RAT;

ANIMALS; CHOLERA TOXIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MALONATES; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; PATCH-CLAMP TECHNIQUES; POLYETHYLENE GLYCOLS; RATS; STILBENES;

EID: 47049088617     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.05.015     Document Type: Article

References (47)

1. Baird E.J., Holowka D., Coates G.W., and Baird B. Highly effective poly(ethylene glycol) architectures for specific inhibition of immune receptor activation. Biochemistry 42 (2003) 12739-12748
2. Barrett K.E., and Keely S.J. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu. Rev. Physiol. 62 (2000) 535-572
3. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23 (2004) 146-158
4. Clarke L.L., Grubb B.R., Gabriel S.E., Smithies O., Koller B.H., and Boucher R.C. Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science 257 (1992) 1125-1128
5. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J. Clin. Invest. 111 (2003) 931-943
6. Gabriel S.E., Brigman K.N., Koller B.H., Boucher R.C., and Stutts M.J. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266 (1994) 107-109
7. Galietta L.J.V., Jayaraman S., and Verkman A.S. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. 281 (2001) C1734-C1742
8. Gestwicki J.E., Cairo C.W., Strong L.E., Oetjen K.A., and Kiessling L.L. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J. Am. Chem. Soc. 124 (2002) 14922-14933
9. Guggino W.B., and Stanton B.A. New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat. Rev. Mol. Cell Biol. 7 (2006) 426-436
10. Handl H.L., Sankaranarayanan R., Josan J.S., Vagner J., Mash E.A., Gillies R.J., and Hruby V.J. Synthesis and evaluation of bivalent NDP-α-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug. Chem. 18 (2007) 1101-1109
11. - channel. Trends Pharmacol. Sci. 20 (1999) 448-453
12. Kramer R.H., and Karpen J.W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 395 (1998) 710-713
13. Krouse M.E., and Wine J.J. Evidence that CFTR channels can regulate the open duration of other CFTR channels: cooperativity. J. Membr. Biol. 182 (2001) 223-232
14. Kunzelmann K., and Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol. Rev. 82 (2002) 245-289
15. - channels expressed in a mammalian cell line and its regulation by a critical pore residue. J. Physiol. 496 (1996) 687-693
16. - secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 66 (2004) 1926-1938
17. Li C., Dandridge K.S., Di A., Marrs K.L., Harris E.L., Roy K., Jackson J.S., Makarova N.V., Fujiwara Y., Farrar P.L., et al. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J. Exp. Med. 202 (2005) 975-986
18. Ma T., Thiagarajah J.R., Yang H., Sonawane N.D., Folli C., Galietta L.J., and Verkman A.S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110 (2002) 1651-1658
19. Mathe J., Aksimentiev A., Nelson D.R., Schulten K., and Meller A. Orientation discrimination of single-stranded DNA inside the α-hemolysin membrane channel. Proc. Natl. Acad. Sci. USA 102 (2005) 12377-12382
20. McCarty N.A. Permeation through the CFTR chloride channel. J. Exp. Biol. 203 (2000) 1947-1962
21. - channel by two closely related arylaminobenzoates. J. Gen. Physiol. 102 (1993) 1-23
22. Migeon-Duballet I., Chabin M., Gautier A., Mistouflet T., Bonnet M., Aubert J.M., and Halphen M. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr. Med. Res. Opin. 22 (2006) 1227-1235
23. Muanprasat C., Sonawane N.D., Salinas D., Taddei A., Galietta L.J., and Verkman A.S. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J. Gen. Physiol. 124 (2004) 125-137
24. Oi H., Matsuura D., Miyake M., Ueno M., Takai I., Yamamoto T., Kubo M., Moss J., and Noda M. Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc. Natl. Acad. Sci. USA 99 (2002) 3042-3046
25. Pal B., Jaisankar P., and Giri V.S. Versatile reagent for reduction of azides to amines. Synth. Commun. 34 (2004) 1317-1323
26. Ramjeesingh M., Kidd J.F., Huan L.J., Wang Y., and Bear C.E. Dimeric cystic fibrosis transmembrane conductance regulator exists in the plasma membrane. Biochem. J. 374 (2003) 793-797
27. Riordan J.R. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67 (2005) 701-718
28. Rosenberg M.F., Kamis A.B., Aleksandrov L.A., Ford R.C., and Riordan J.R. Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 279 (2004) 39051-39057
29. Routaboul C., Norez C., Melin P., Molina M.C., Boucherle B., Bossard F., Noel S., Robert R., Gauthier C., Becq F., and Décout J.L. Discovery of alpha-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels. J. Pharmacol. Exp. Ther. 322 (2007) 1023-1035
30. Schillers H., Shahin V., Albermann L., Schafer C., and Oberleithner H. Imaging CFTR: a tail to tail dimer with a central pore. Cell. Physiol. Biochem. 14 (2004) 1-10
31. - channels expressed in a murine cell line. J. Physiol. 503 (1997) 333-346
32. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J. Gen. Physiol. 100 (1992) 573-591
33. Sonawane N.D., Muanprasat C., Nagatani R., Song Y., and Verkman A.S. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J. Pharm. Sci. 94 (2005) 134-143
34. Sonawane N.D., Hu J., Muanprasat C., and Verkman A.S. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J. 20 (2006) 130-132
35. Sonawane N.D., Zhao D., Zegarra-Moran O., Galietta L.J., and Verkman A.S. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 132 (2007) 1234-1244
36. Sonawane N.D., Zegarra-Moran O., Namkung W., Galietta L.J., and Verkman A.S. α-Aminoazaheterocyclic-methylglyoxal adducts do not inhibit cystic fibrosis transmembrane conductance regulator chloride channel activity. J. Pharmacol. Exp. Ther. 325 (2008) 529-535
37. Staudinger H., and Meyer J. New organic compounds of phosphorus. III. Phosphinemethylene derivatives and phosphinimines. J. Helv. Chim. Acta. 2 (1919) 635-646
38. Taddei A., Folli C., Zegarra-Moran O., Fanen P., Verkman A.S., and Galietta L.J. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett. 558 (2004) 52-56
39. Takeda T., Takeda Y., Miwatani T., and Ohtomo N. Detection of cholera enterotoxin activity in suckling hamsters. Infect. Immun. 19 (1978) 752-754
40. Thiagarajah J.R., and Verkman A.S. New drug targets for cholera therapy. Trends Pharmacol. Sci. 26 (2005) 172-175
41. Thiagarajah J.R., Broadbent T., Hsieh E., and Verkman A.S. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126 (2003) 511-519
42. Walsh K.B., Long K.J., and Shen X. Structural and ionic determinants of 5-nitro-2-(3-phenylprophyl-amino)-benzoic acid block of the CFTR chloride channel. Br. J. Pharmacol. 127 (1999) 369-376
43. Wang S., Yue H., Derin R.B., Guggino W.B., and Li M. Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. Cell 103 (2000) 169-179
44. Woodhull A.M. Ionic blockage of sodium channels in nerve. J. Gen. Physiol. 61 (1973) 687-708
45. Yang B., Sonawane N.D., Zhao D., Somlo S., and Verkman A.S. Small-molecule CFTR inhibitors slow cyst growth in culture and mouse models of polycystic kidney disease. J. Am. Soc. Nephrol. 19 (2008) 1300-1310
46. Zerhusen B., Zhao J., Xie J., Davis P.B., and Ma J. A single conductance pore for chloride ions formed by two cystic fibrosis transmembrane conductance regulator molecules. J. Biol. Chem. 274 (1999) 7627-7630
47. Zhou Z., Hu S., and Hwang T.C. Probing an open CFTR pore with organic anion blockers. J. Gen. Physiol. 120 (2002) 647-662